14 hrs ago
Promoter Stake Sales Draw Institutional Interest in Three Indian Stocks
Three companies had large shareholders sell some of their shares.
Big investment funds and other institutions bought many of those shares.
This happened soon after the companies reported better quarterly results.
Jamna Auto wants to grow beyond its traditional dependence on commercial-vehicle manufacturers.
Gland Pharma is trying to expand into specialized drug manufacturing and CDMO work.
Granules India is increasing its focus on complex medicines and peptide manufacturing.
The funds may be interested in how these businesses could grow in the future.
However, buying by institutions does not guarantee that the stocks will perform well.
Investors still need to watch execution, valuations, and company-specific risks.
Promoters sold sizeable stakes in Jamna Auto Industries, Gland Pharma, and Granules India during September.
Institutional buyers included DSP Mutual Fund, Kotak Mutual Fund, ICICI Prudential AMC, and Capital Group’s Smallcap World Fund.
All three companies reported stronger Q1FY27 revenue, profitability, or business-mix improvements before the transactions.
Jamna Auto is targeting faster growth through exports, aftermarket sales, and higher-value suspension products.
Gland Pharma and Granules India are expanding into higher-barrier CDMO, complex-generics, and peptide businesses, though risks remain.
- Who
- Promoters of Jamna Auto Industries, Gland Pharma, and Granules India sold stakes, while mutual funds, asset managers, insurers, and other institutional investors bought shares.
- What
- Three September block deals transferred sizeable promoter holdings to institutional investors after the companies reported improved quarterly performance.
- Where
- The transactions involved Indian-listed companies; Jamna Auto’s acquisition target, Owen Springs, is based in the United Kingdom.
- When
- The deals occurred on September 4 and September 11; valuation data was stated as of September 16, 2026, and the results discussed were for Q1FY27.
- Why
- Promoters sold shares, while institutions appear to have used the transactions to gain exposure to businesses showing stronger earnings and potential shifts toward higher-growth activities.
Institutional-growth case
Valuation-and-execution caution
Meaning of the block deals
Institutional-growth case
Institutions may have used promoter sales to build positions in companies whose earnings, margins, and business mix are improving.
Valuation-and-execution caution
The purchases may simply have provided liquidity for large sellers and should not automatically be treated as a buy signal.
Future growth plans
Institutional-growth case
Jamna Auto’s exports and aftermarket expansion, Gland Pharma’s CDMO pipeline, and Granules India’s complex-generics and peptide businesses could improve long-term growth and business quality.
Valuation-and-execution caution
These plans still have to produce sustained revenue and profits; Jamna must scale new businesses, Gland must grow CDMO operations, and Granules must maintain its improvements.
Price and risk
Institutional-growth case
Jamna Auto’s valuation was below its five-year median, while stronger future earnings could support the institutional interest in all three companies.
Valuation-and-execution caution
Gland Pharma and Granules India traded above their historical valuation medians, and the companies face risks including Gland’s US-business volatility, Jamna’s expansion uncertainty, and a US FDA notice affecting Granules.
Key facts
- Jamna Auto deal
- Pradeep Singh Jauhar and Randeep Singh Jauhar sold a combined 5% stake on September 11 at ₹128 per share.
- Gland Pharma deal
- Fosun Pharma sold a 6% stake on September 4 in a deal worth roughly ₹2,800 crore, reducing its holding below 50%.
- Granules India deal
- Chairman Krishna Prasad Chigirupati sold nearly 7% for around ₹1,509 crore on September 11.
- Jamna Auto Q1FY27
- Revenue rose 7% year over year to ₹612 crore, while EBITDA increased 12.8% to ₹88 crore.
- Gland Pharma Q1FY27
- Revenue rose 19.6% to ₹1,800 crore, net profit increased 47.8% to ₹317 crore, and EBITDA margin reached 27.4%.
- Granules India Q1FY27
- Revenue rose 22% to ₹1,477 crore, EBITDA increased 37.4% to ₹338.9 crore, and net profit rose 59.3% to ₹180 crore.
- Valuations
- Jamna Auto traded at 20.7 times earnings versus a five-year median of 24.4; Gland Pharma at 40.9 versus 38.2; and Granules India at 32.7 versus 24.4.
Sources
Related news
Fosun Pharma Stake Sale Takes Holding Below 50%
Five Vijay Kedia Portfolio Stocks With Changing Growth Prospects
Stocks in News: Gaja Debut, Block Deals, New Orders
Amrutanjan and Jagsonpal Offer Contrasting Cash-Return Investment Cases
Vallabh Bhanshali’s Four-Stock Portfolio Hides Value—and Significant Risks
Tata Consumer, Rallis India Hit Lows Despite Profit Growth
Ajit Mishra Recommends Trades in Granules, HAL and HUL Shares
GIFT Nifty Signals Gap-Down Start as Crude Rises
Indian Pharma Seeks US Engagement After Trump's Tariff Plan
Granules India Focuses on Injectables and M&A
